Clinical Trials
42 trialsTQB2618 Injection Combined With Penpulimab Injection in the Treatment of Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab+Chemotherapy in Advanced Solid Tumors - Cohort C
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
A Phase II Clinical Trial of Anti-EGFR Antibody-drug Conjugate (ADC) Combined With or Without Immune Checkpoint Inhibitors in the Neoadjuvant Treatment of Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma
West China Hospital
ALTER-HN005
Sun Yat-sen University
Anlotinib Plus Penpulimab as Second-line Treatment for Patients With Small Cell Lung Cancer After Failure of Platinum-based Chemotherapy
Hunan Cancer Hospital
Clinical Studies for the Treatment of Advanced Solid Tumors
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
SPARC
Ruijin Hospital
JDB153 Combined With Penpulimab for Hepatocellular Carcinoma After Standard Treatment Failure
West China Hospital
AK129 Combination Therapy for Advanced Solid Tumors
Akeso
A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma
Akeso
LARC-nCR01
The First Affiliated Hospital with Nanjing Medical University
TQB2928 Injection Combined With Penpulimab in Treatment of Advanced Malignant Tumors.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCL
The First Affiliated Hospital with Nanjing Medical University
Irinotecan Plus Anlotinib or Further in Combination With Penpulimab for Second-line Treatment of mCRC
Fudan University
PAAG
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Anlotinib Combined With Penpulimab as Front-line Treatment in Advanced Non-small Cell Lung Cancer
The First Affiliated Hospital of Zhengzhou University
A Clinical Study of TQB2618 Injection Monotherapy and Combination Regimen (With Penpulimab Injection ±Anlotinib Hydrochloride Capsules) in the Four or Later Lines of Treatment of Advanced Colorectal Cancer.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
ALTER-GO-020
Sichuan Cancer Hospital and Research Institute
EXPLORING
The First Affiliated Hospital with Nanjing Medical University
PROMIS
Ruijin Hospital
Penpulimab Combined With Chemotherapy for Neoadjuvant and Adjuvant Therapy in Patients With Resectable HNSCC
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Study of Anlotinib in Patients With Radioiodine Refractory Differentiated Thyroid Cancer
Peking Union Medical College Hospital
RCT-PAAG
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
A Single Center, Single Arm Clinical Study on the Treatment of Advanced Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations and Failed EGFR TKIs With the Combination of Enrotinib and Paclitaxel Monoclonal Antibody
Qianfoshan Hospital
A Clinical Trial of TQB2618 Injection Combined With Penpulimab Injection and Chemotherapy Versus Penpulimab Injection Combined With Chemotherapy in First-line Treatment of Relapsed/Metastatic Head and Neck Squamous Cell Carcinoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
The Efficacy and Safety of Penpulimab in the Treatment of Metastatic PPGL Patients Who Fail to Other Systemic Treatment
Peking Union Medical College Hospital
Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Gut Microbial Metabolites Inosine Combined With PD-1/PD-L1 Inhibitor for Patients With Malignant Advanced Solid Tumors
Beijing Friendship Hospital
To Evaluate the Safety and Efficacy of TQB2618 Injection Combined With Penpulimab in the Treatment of Patients With Relapsed and Refractory Lymphoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Disitamab Vedotin(RC48) Combined With Penpulimab(AK105) for Neoadjuvant Treatment of HER2-low Breast Cancer
West China Hospital
Penpulimab in Maintenance Therapy in Lymphoma
The First Affiliated Hospital with Nanjing Medical University
Exploratory Clinical Study of Penpulimab Combined With SOX in the Perioperative Treatment of Gastric Cancer
The Central Hospital of Lishui City
A Clinical Study of Disitamab Vedotin for Injection Combined With Penpulimab Injection in Neoadjuvant Therapy for Patients With HER2-expressing Cisplatin-intolerant cT2-T4aNxM0 Bladder Urothelial Carcinoma
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Anlotinib , Penpulimab Combined With SBRT for Metastatic Non-Small Cell Lung Cancer (NSCLC)
Peking University Third Hospital
Anlotinib Plus Penpulimab in Advanced Non-Small-Cell Lung Cancer Previously Treated With PD-1/PD-L1 Inhibitors
Hunan Cancer Hospital
AK105 Plus Anlotinib Hydrochloride Combined With Albumin Paclitaxel as a First-line Therapy in Patients With Advanced Triple-negative Breast Cancer
Liaoning Cancer Hospital & Institute
AP
The First Affiliated Hospital of Xinxiang Medical College
ALTER-C003
Peking Union Medical College Hospital
Penpulimab Plus R2-GemOx Regimen in Relapsed or Refractory DLBCL
The First Affiliated Hospital with Nanjing Medical University
Decitabine Plus Penpulimab as Second-line Therapy for Advanced ESCC Treated With PD-1 Blockade
The First Affiliated Hospital of Zhengzhou University
Anlotinib or Penpulimab in Combination With RAI for DTC
Peking Union Medical College Hospital
AK105 Combined With Anlotinib in Patients With Cervical Cancer
The First Affiliated Hospital of Zhengzhou University